Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03742011
Other study ID # 2018101502
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2012
Est. completion date December 31, 2038

Study information

Verified date February 2024
Source Guangzhou Women and Children's Medical Center
Contact Xiu Qiu, PhD
Phone 0086 20 38367160
Email qxiu0161@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Offspring Born to Mothers with Polycystic Ovary Syndrome in Guangzhou Cohort study (PCOS-BIG) was established to investigate the short- and long-term effects of intrauterine exposure to maternal PCOS on the health of offspring in Guangzhou, China. Data are collected regarding maternal PCOS subtypes, nursing, diet and education as well as health outcomes in their later life. Biological samples including blood and tissue samples are also collected from participants.


Description:

According to preliminary survey, the prevalence of polycystic ovary syndrome (PCOS) among Chinese women reached 7.5%. Hyperandrogenism and insulin resistance were considered as the main pathogenesis of PCOS. As reported, the secretion of androgen is higher among women with PCOS than the healthy reference population throughout their fertile lives. Worth of concern, offspring of PCOS patients presented with glucolipid metabolism disorders as early as during their childhood, while whose pathogenesis remains unclear. Prenatal exposure of rhesus monkey in pregnant to androgens produces glucolipid metabolic alterations in offspring resembling those in PCOS, suggesting that the exposure of the fetus to hyperandrogenism during gestation could affect the glucolipid metabolism of PCOS offspring. Growing evidence shows that different exposures during pregnancy will affect the DNA methylation of offspring and disturb their endocrine and metabolism. A birth cohort would provide an opportunity to examine the short- and long-term effects of PCOS exposure, such as hyperandrogenism, on health consequences of the offspring.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date December 31, 2038
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: - Offspring born to women diagnosed with PCOS - Offspring born to women with <20 weeks of gestation, intended to eventually deliver in Guangzhou Women and Children's Medical Center - Permanent residents or families intended to remain in Guangzhou for =3 years Exclusion Criteria: - None

Study Design


Locations

Country Name City State
China Guangzhou Women and Children's Medical Center, China Guangzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Guangzhou Women and Children's Medical Center University of Birmingham

Country where clinical trial is conducted

China, 

References & Publications (2)

Qiu X, Lu JH, He JR, Lam KH, Shen SY, Guo Y, Kuang YS, Yuan MY, Qiu L, Chen NN, Lu MS, Li WD, Xing YF, Zhou FJ, Bartington S, Cheng KK, Xia HM. The Born in Guangzhou Cohort Study (BIGCS). Eur J Epidemiol. 2017 Apr;32(4):337-346. doi: 10.1007/s10654-017-02 — View Citation

Zhou Z, Li R, Qiao J. Androgen profile in Chinese women with polycystic ovary syndrome in their reproductive years. Reprod Biomed Online. 2017 Sep;35(3):331-339. doi: 10.1016/j.rbmo.2017.05.019. Epub 2017 Jun 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Abnormal Laboratory Values (Glucolipid metabolism disorders) Participants with one or more abnormal laboratory values will be considered as with glucolipid metabolism disorder. An average of 3 years old
Secondary Prevalence of gestational diabetes, pregnancy induced hypertension, and cesarean section Assessed by self-reported time of onset and electronic medical records From the recruitment (= 20 weeks of gestation) to delivery
Secondary Prevalence of stillbirth, preterm birth, small for gestational age, large for gestational age and birth defect Assessed by electronic medical records At delivery
Secondary Epigenetic profiles of offspring Profiling DNA methylation and histone acetylation etc., using cord blood samples At birth
Secondary Weight changes Weight changes from birth, to age of 6 weeks, 6 months, 1 year, 3 years, 6 years, 12 years and 18 years old At birth, age of 6 weeks, 6 months, 1 year, 3 years, 6 years, 12 years and 18 years old
Secondary Height changes Height changes from birth, to age of 6 weeks, 6 months, 1 year, 3 years, 6 years, 12 years and 18 years old At birth, age of 6 weeks, 6 months, 1 year, 3 years, 6 years, 12 years and 18 years old
Secondary Change of intestinal flora Assessed by analyses of stool samples At age of 6 weeks, 6 months, 1 year, 3 years, 6 years, 12 years and 18 years old
Secondary Neurodevelopment at early childhood Assessed using Gesell Developmental Schedules, including five items of adaptive, gross motor, fine motor, language, and social function At age of 1 year old
Secondary Changes of the percentage of body fat Assessed using Dual Energy X-Ray Absorptiometry At age of 3 years,6 years, 12 years and 18 years old
Secondary Screen of intelligence quotient of offspring Assessed using Peabody Picture Vocabulary Test (PPVT) and Raven's Standard Progressive Matrices (SPM). Of whom the score of PPVT = 85 and the score of SPM = 90, the child will be considered as normal level of intelligence quotient and of whom the score of PPVT under 85 or the score of SPM under 90 will be considered as suspected lower intelligence quotient. At age of 6 years old
Secondary Intelligence quotient of offspring assessed by WPPSI-IV Child screened as of suspected lower intelligence quotient will be assessed by Wechsler Preschool and Primary Scale of Intelligence-Fourth edition (WPPSI-IV), including 5 items: verbal comprehension, visual spatial, fluid reasoning, working memory and process speed. Scores of the five items are added to get the total score. At age of 6 years old
Secondary Number of Participants With Abnormal Laboratory Values (Glucolipid metabolism disorders) Participants with one or more abnormal laboratory values will be considered as with glucolipid metabolism disorder. At age of 6 years, 12 years and 18 years old
Secondary Number of participants with reproductive endocrine disorders Assessed by assay of hormones, including follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), total testosterone (TT), free testosterone (FT), androstenedione (A4), dehydroepiandrosterone sulfate (DHEA-S) and sex hormone binding globulin (SHBG), and by acne scoring and hirsutism scoring (modified Ferriman-Gallway scoring system). Participants with one or more abnormal laboratory values, and/or acne score = 1, and/or hirsutism score = 5 will be considered as with reproductive endocrine disorder. At age of 12 years and 18 years old
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04203238 - Potato Research for Enhancing Metabolic Outcomes N/A
Recruiting NCT03658564 - Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance N/A
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Completed NCT04642482 - Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Withdrawn NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Phase 4
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A